07:49 AM EDT, 07/15/2024 (MT Newswires) -- Scinai Immunotherapeutics ( SCNI ) said on Monday that preclinical study results of its experimental therapy for mild to moderate plaque psoriasis showed efficacy.

The study's data showed that Scinai's therapy had a non-inferior anti-inflammatory effect on the psoriatic lesions compared to corticosteroids and systemic biologics.

The drug developer's shares rose nearly 45% to $5.89 in premarket trading.

Price: 6.2200, Change: +2.16, Percent Change: +53.20